ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0396

Inflammatory Markers of Autoimmune Uveitis in the Eye, Tears and Blood

Maryrose Hahn1, Madison Mangin2, Kellen Winden3, Pui Lee4, Mindy Lo2, Bharti Nihalani-Gangwani2, Yasmin Massoudi5, Tate Valerio5, Amanda Colombo5, Jessica Scott6, Stephen Anesi6, C. Stephen Foster6, Peter Nigrovic7, sheila Angeles-Han8, Peter Chang6 and Margaret Chang2, 1Boston Children's Hospital, Georgetown, MA, 2Boston Children's Hospital, Boston, MA, 3Boston Children's Hospital, Boston, MA, 4Boston Children's Hospital, Newton, MA, 5Massachusetts Eye Research and Surgery Institution, Waltham, MA, 6Massachusetts Eye Research and Surgery Institution, Waltham, 7Boston Children's Hospital, Brookline, MA, 8Cincinnati Children's Hospital, Cincinnati, OH

Meeting: ACR Convergence 2024

Keywords: Biomarkers, cytokines, Eye Disorders, Inflammation, Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Pediatric Rheumatology – Clinical Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Autoimmune uveitis is an inflammatory disorder of the eye that is associated with significant morbidity, including vision-threatening complications and chronic reliance on immunosuppressive therapies. Evaluation of ocular inflammation is largely based on clinical ophthalmic examinations. Our aim is  to discover potential biomarkers of disease through biological samples such as aqueous humor (AQH), blood and tear fluid.

Methods: We obtained AQH samples paired with tears and blood from adult and pediatric patients with uveitis or non-inflammatory conditions undergoing eye surgery at Boston Children’s Hospital, Massachusetts Eye Research & Surgery Institution, and Cincinnati Children’s Hospital Medical Center. We also collected clinical information such as slit-lamp examinations to grade uveitis activity at the time of surgery. Cytokine and immune-related protein content of biological samples was assessed through Olink proximity extension multiplex immunoassay. The intraocular cytokine profiles of (AQH samples were compared across patients by generalized linear models (LIMMA) on log2 transformed data and assigned inflammatory scores based on the sum of normalized cytokine values. Samples were grouped by uveitis subtype and AQH inflammatory scores. Paired AQH and blood samples and paired AQH and tear samples collected at the time of surgery were evaluated for overlapping inflammatory protein content. Immune-related protein expression in the blood and tear samples were correlated to AQH inflammatory scores.

Results: We evaluated AQH samples from controls (n=16) and patients with anterior uveitis (n=16), intermediate uveitis (n=2), posterior uveitis (n=4), and panuveitis (n=7). At the time of sample collection, all patients had near-quiet disease activity on slit-lamp examination with anterior chamber cell grades between 0 and 0.5+ by SUN criteria. Non-inflammatory control patients displayed low cytokine levels in their AQH, while 44% of patients with anterior uveitis (n=7) and 57% of patients with panuveitis (n=4) had evidence of ongoing inflammation. The cytokine profile did not overlap between paired AQH and tears (n=7) or paired AQH and blood samples (n=14). There was also no direct correlation between immune-related proteins in the blood or tears with their paired AQH inflammatory scores, although some markers such as IL7 and CSF3 in the blood and VEGFA in the tears trended towards significance. Notably, pediatric uveitis patients showed more AQH inflammation compared to adults, as 86% of children with anterior uveitis and 100% of children with panuveitis had AQH inflammation, compared to 11% and 50% in adults, respectively.

Conclusion: Our findings demonstrate that ~50% of anterior and panuveitis patients have elevated inflammatory protein levels in AQH despite having quiescent clinical examinations. Strikingly, the majority of pediatric patients with anterior and panuveitis exhibited subclinical eye inflammation, in contrast to adults with uveitis. This emphasizes the need for more sensitive methods of assessing uveitis activity by examination or imaging-based methods, as well as identifying reliable biomarkers of disease activity.


Disclosures: M. Hahn: None; M. Mangin: None; K. Winden: None; P. Lee: None; M. Lo: None; B. Nihalani-Gangwani: None; Y. Massoudi: None; T. Valerio: None; A. Colombo: None; J. Scott: None; S. Anesi: None; C. Foster: None; P. Nigrovic: American Academy of Pediatrics, 9, Bristol-Myers Squibb(BMS), 5, Century Therapeutics, 2, Edelweiss Immuno, 8, Fresh Tracks Therapeutics, 2, Merck/MSD, 2, Monte Rosa Therapeutics, 2, Novartis, 2, Pfizer, 2, 5, Qiagen, 2, Sobi, 2, UpToDate, 9; s. Angeles-Han: None; P. Chang: None; M. Chang: None.

To cite this abstract in AMA style:

Hahn M, Mangin M, Winden K, Lee P, Lo M, Nihalani-Gangwani B, Massoudi Y, Valerio T, Colombo A, Scott J, Anesi S, Foster C, Nigrovic P, Angeles-Han s, Chang P, Chang M. Inflammatory Markers of Autoimmune Uveitis in the Eye, Tears and Blood [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/inflammatory-markers-of-autoimmune-uveitis-in-the-eye-tears-and-blood/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inflammatory-markers-of-autoimmune-uveitis-in-the-eye-tears-and-blood/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology